Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical passes the values gate
Price385.12 USD
Fair value274.71
Ethical score70.0/100
Our investment reviews on this name
2026-10-29Read Markup385.12+0.0% to today ✓Distribution gives way to Markup after an 8% rise in 3 weeks
2026-10-11Read Distribution355.57+8.3% to today Markdown gives way to Distribution
2026-10-02Read Markdown355.57+8.3% to today Accumulation gives way to Markdown
2026-08-23Read Accumulation342.43+12.5% to today ✓Markup gives way to Accumulation after a 20% rise in 7 weeks
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Bio-Rad Laboratories, Inc. holds its Markup at $385.12. The statistical read favours the buyers, held for 90 days.
As held on the ledger · 2026-10-28
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 90 days
Price at the screen
$385.12
Valuation
44.72 trailing · 36.20 forward price to earnings
Values screen
PASS· score 70.0
Beta
1.07
The Workings
Five Screens, Shown in Full
Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
13.11%
Below 33%
Interest-bearing debt is just 13.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
9.56%
Below 33%
Cash held in interest-bearing accounts and securities is 9.6% of assets, under the one-third limit.
Pass
Receivables
9.36%
Below 49%
Money owed to the company is 9.4% of assets, under the 49% limit.
Pass
Revenue purity
3.70%
Below 5%
Only 3.7% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Clears, in Plain English
Bio-Rad Laboratories, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 13%, inside the ~33% line, and interest is about 4% of its income, under the ~5% line, so it passes.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BIO's ethical verdict changes
Today BIO passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-28 screen. The gold marker is the market price at the same screen. The price runs 28.7% above the base estimate.
Third-party analyst targets: 3 covering, consensus Hold. The average target sits −13% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-28 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Lab supplier priced for growth it cannot deliver
Picture a hospital running blood tests or a researcher mixing samples. The gear comes from specialists like Bio-Rad that ship instruments and reagents across continents. Yet the shares sit at 304 dollars against a fair value near 257, a 16 percent premium that leaves no margin for error. Forward earnings sit at 31 times while revenue edges up just 1 percent a year, so the market is paying top dollar for very little momentum.
The business clears the ethical screen, yet the numbers tell a different story. Profit margins rest at 7 percent and return on equity is only 2 percent, both thin for a medical device name with an unknown competitive moat. Five analysts call the stock a hold with a 300 dollar median target, which still leaves it expensive on any reasonable measure of cash generation or growth.
Risk sits in the valuation itself. Low returns and single-digit growth rarely support such multiples for long, and any slowdown in lab spending would quickly expose the gap between price and underlying performance. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BIO trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Markup · changed$385.12+9.2%Entry 11
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 9.2% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it hold, with a mean price target of $297. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Distribution$352.82+0.0%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 19% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it hold, with a mean price target of $297. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Distribution$352.82-3.3%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 3.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 14% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it hold, with a mean price target of $297.
2026-10-18Distribution$364.82+2.6%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 2.6% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it hold, with a mean price target of $297.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it hold, with a mean price target of $297.
2026-10-02Markdown · changed$355.57+3.8%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 3.8% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it hold, with a mean price target of $297.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 12.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it hold, with a mean price target of $297.
2026-07-23Markup$304.36+6.4%Entry 4
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.4% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it hold, with a mean price target of $297.
2026-07-18Markup$285.94+0.0%Entry 3
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 24%. The street (5 analysts) rates it hold, with a mean price target of $297.
2026-07-03Markup$285.94+0.0%Entry 2
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
